publication date: Nov. 11, 2016

Funding Opportunities Genentech, SU2C Provide Research Funding, Access to 12 Compounds

SU2C and Genentech announced a Catalyst collaboration aimed at accelerating the development of new cancer treatments and combination therapies by providing funding and access to a dozen of the company’s medicines.

Genentech is a member of the Roche Group. There have been previous SU2C Catalyst collaborations with Merck and Bristol-Meyers.

The program managed by SU2C’s Scientific Partner, the American Association for Cancer Research, is intended to leverage all facets of the pharmaceutical, biotechnology, diagnostic, and devices industries to bring new treatments to patients as rapidly as possible through early-phase clinical trials or translational research.

Each SU2C Catalyst project is carried out by a collaborative team of expert investigators. The project must be designed to accelerate the clinical use of therapeutic agents or methods leading to patient involvement within the three-year term of the grant, and to deliver near-term patient benefit, according to the program’s guidelines.

The Genentech-supported projects will support research into new uses for 12 approved or investigational medicines: atezolizumab (Tecentriq), bevacizumab (Avastin) (combinations only), alectinib (Alecensa), cobimetinib (Cotellic), vemurafenib (Zelboraf), vismodegib (Erivedge), trastuzumab (Herceptin) plus pertuzumab (Perjeta), obinutuzumab (Gazyva), emactuzumab, anti-CD40, or idasanutlin.

Each of these medicines can be investigated alone or in combination with other compounds, biologics, diagnostics, or devices intended as therapeutic interventions, and/or methods for biomarker identification in the following thematic areas of research:

Continue reading Genentech, SU2C Provide Research Funding, Access to 12 Compounds

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.